Ekso Bionics reports record 2023 revenue of $18.3M, up 42% YoY

EKSO BIONICS HOLDINGS, INC.

Full-year 2023 revenue $18.3M (FY22: $12.9M); sold 151 EksoHealth units.
Q4 2023 revenue $4.8M (+36% YoY); gross margin 49% vs 47%.
Net loss FY23 $15.2M ($1.10/sh) vs $15.1M ($1.16/sh) in FY22.
Cash at Dec 31, 2023: $8.6M, down from $20.5M; raised $3.9M in Jan 2024 offering.
CMS deferred payment determination for personal exoskeletons (Ekso Indego Personal).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EKSO BIONICS HOLDINGS, INC. reported financial results for three and twelve months ended December 31, 2023.

Period: three and twelve months ended December 31, 2023
Result: reported results

Exact text from the filing

On March 4, 2024 Ekso Bionics Holdings, Inc. (the “Company”) reported its financial results for the three and twelve months ended December 31, 2023. The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-006421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.